Madsen Malene Galle, Zhu Jin Liang, Munk-Olsen Trine, Wimberley Theresa, Larsson Henrik, Rommel Anna-Sophie, Liu Xiaoqin, Kjeldsen Mette-Marie Zacher, Kittel-Schneider Sarah, Bergink Veerle, Madsen Kathrine Bang
National Centre for Register-based Research, Aarhus University, Fuglesangs Allé 26, 8210, Aarhus V, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Paediatr Drugs. 2025 Mar;27(2):233-246. doi: 10.1007/s40272-024-00671-5. Epub 2025 Jan 13.
Females of reproductive age are increasingly using attention deficit hyperactivity disorder (ADHD) medication, but its use during pregnancy and breastfeeding is largely unknown. The aim of this study is to examine the prevalence of ADHD medication fills during pregnancy and breastfeeding, including characteristics of these females and cohort differences over time.
We conducted a descriptive study using Danish nationwide registers. Within cohorts of pregnant and breastfeeding females, we calculated the prevalence of ADHD medication (methylphenidate, amphetamine, dexamfetamine, lisdexamfetamine, modafinil, atomoxetine, clonidine and guanfacine) fills and described sociodemographic and clinical characteristics across groups with fills, no fills and previous fills. Cohort differences in ADHD medication fills during pregnancy for 2005-2010, 2011-2016 and 2017-2022 were examined.
In this cohort of 1,077,279 pregnancies, ADHD medication fills increased from 0.08 to 7.71 per 1000 individuals between 2005 and 2022. Among 446,485 breastfeeding females, fills increased from 0.55 to 3.67 per 1000 individuals from 2012 to 2022. Compared with the group with no fills, females filling ADHD medication during pregnancy and breastfeeding were younger, had lower levels of education, were more often smoking during pregnancy, utilised more psychiatric healthcare and had concurrent fills of other psychotropic medication. Cohort differences over time revealed that females filling ADHD medication during pregnancy in 2017-2022 were older, had higher levels of education, smoked less during pregnancy, had fewer psychiatric contacts and were less likely to fill other psychotropic medications compared with females in the earlier cohorts.
Results showed an increasing prevalence of ADHD medication fills during pregnancy and breastfeeding in Denmark over time, surpassing the increase observed generally in females of reproductive age filling ADHD medication. Results revealed a difference in characteristics of females filling ADHD medication during pregnancy over time, suggesting a shift in pregnancy treatment patterns.
育龄女性越来越多地使用注意力缺陷多动障碍(ADHD)药物,但其在孕期和哺乳期的使用情况在很大程度上尚不明确。本研究的目的是调查孕期和哺乳期使用ADHD药物的流行情况,包括这些女性的特征以及随时间推移的队列差异。
我们使用丹麦全国性登记数据进行了一项描述性研究。在怀孕和哺乳期女性队列中,我们计算了ADHD药物(哌甲酯、苯丙胺、右旋苯丙胺、赖右苯丙胺、莫达非尼、托莫西汀、可乐定和胍法辛)的使用流行率,并描述了有用药、未用药和既往用药组的社会人口统计学和临床特征。研究了2005 - 2010年、2011 - 2016年和2017 - 2022年孕期ADHD药物使用的队列差异。
在这个包含1,077,279例妊娠的队列中,2005年至2022年间,每1000人中ADHD药物的使用从0.08增加到7.71。在446,485名哺乳期女性中,2012年至2022年间,每1000人中的使用从0.55增加到3.67。与未用药组相比,孕期和哺乳期使用ADHD药物的女性更年轻,受教育程度较低,孕期吸烟更频繁,使用更多的精神科医疗服务,并且同时使用其他精神药物。随时间推移的队列差异显示,与早期队列中的女性相比,2017 - 2022年孕期使用ADHD药物的女性年龄更大,受教育程度更高,孕期吸烟更少,精神科就诊次数更少,并且使用其他精神药物的可能性更小。
结果显示,丹麦孕期和哺乳期使用ADHD药物的流行率随时间增加,超过了育龄女性中一般观察到的使用ADHD药物的增加幅度。结果揭示了孕期使用ADHD药物的女性特征随时间的差异,表明孕期治疗模式发生了转变。